552 results about "HIV Positivity" patented technology

The invention discloses an anti-PD-L1 antibody coupling drug and a preparation method thereof, belongs to the field of biological medicines, and is used for preparing anti-cancer drugs. The antibody coupling medicine is formed by coupling an anti-PD-L1 antibody and a payload through a linker, a light chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 1, a heavy chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 2, the payload is an avixatecan derivative Dxd, and the ratio (DAR) of the payload to the antibody is 6-8. The antibody-conjugated drug has a better killing effect on PD-L1 positive tumor cells of human and dogs, and has fewer dimers and higher thermal stability at a high DAR value (DAR6-8), and an accelerated stability test shows that the antibody-conjugated drug has good structural stability and binding activity.

The invention belongs to the technical field of immunology and in vitro diagnosis, and relates to a monoclonal antibody aiming at bovine nodular skin disease virus (LSDV) L1R protein. According to the invention, the LSDV recombinant L1R protein with deletion of a transmembrane region (182-204aa) is obtained through expression; after a mouse is immunized by the protein, a monoclonal antibody 8D5 which is good in reactivity and specificity and aims at the LSDV L1R protein is screened out; heavy chain and light chain variable region sequences for coding the monoclonal antibody 8D5 are obtained; the monoclonal antibody 8D5 can be subjected to specific reaction with LSDV L1R protein, the recombinant protein L1R can be specifically recognized by bovine LSDV positive serum, meanwhile, the monoclonal antibody 8D5 can be used for establishing an LSDV ELISA antibody detection method, and a foundation is laid for LSDV diagnostic technology and vaccine research and development.

The invention provides a primer probe group for simultaneously detecting American strains and European strains of porcine reproductive and respiratory syndrome viruses, a detection method and application, and particularly belongs to the technical field of porcine pathogen detection products. The invention provides a primer probe group for simultaneously detecting American strains and European strains of porcine reproductive and respiratory syndrome viruses. The primer probe group comprises universal forward primers PRRSV1-F and PRRSV2-F for detection, reverse primers PRRSV1-R and PRRSV2-R for detection and a universal probe PRRSV-P. A target gene detected by the primer probe group is a 3'non-coding region gene (3 'UTR) of a porcine reproductive and respiratory syndrome virus genome, and the primer probe group can realize efficient detection of American strains and European strains of the porcine reproductive and respiratory syndrome virus, and is simple and convenient in detection, high in sensitivity, good in specificity, high in speed, low in false positive and capable of realizing high-throughput detection.

The invention discloses a PD-L1 immunohistochemical quality control product and a preparation method thereof, and relates to the technical field of biology. The PD-L1 immunohistochemical quality control product comprises cell slices prepared from a plurality of different types of tumor cells, the cell section comprises a positive quality control product and a negative quality control product which are marked by different colors. In the invention, different tumor cells are creatively adopted as raw materials of the quality control product, the quality control product can be efficiently and quickly prepared, and the limitation of the source of a human tissue sample is overcome; a BSA sealing buffer solution is used for soaking the section, so that long-term stable production of a quality control product can be realized, the dyeing background is reduced, and the dyeing effect is enhanced; besides, by preparing the cell slices with various proportions and different staining intensities, the quality control on the staining of the antibody can be ensured, and guidance can also be provided for accurate interpretation, namely comprehensive and accurate quality control and interpretation guidance are provided for the staining of the antibody, false negative and false positive are effectively eliminated, and the method has great clinical significance.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1D3 for detecting a porcine epidemic diarrhea virus antibody and application of the monoclonal antibody 1D3. The CDR sequences of the heavy chain variable region are respectively shown as SEQ ID NO.1-3, and the CDR sequences of the light chain variable region are respectively shown as SEQ ID NO.4-6. The antibody can specifically recognize PEDV / S1 protein, binding of the antibody can be competitively blocked by a PEDV specific neutralizing antibody in serum, and the antibody is suitable for establishing a blocking ELISA method. A detection tool based on the antibody has high specificity and sensitivity, and the blocking rate to PEDV positive serum is higher than 50%. The invention can be used for preparing a detection kit or evaluating the immune effect of a vaccine, and provides an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention discloses preparation of a human CD56 immune phage display antibody library, which comprises the following steps: S1, animal immunization: expressing recombinant hCD56 protein in escherichia coli, then immunizing a Balb / c mouse, and detecting immune titer; s2, splenocyte preparation: extracting RNA (Ribonucleic Acid) of immune mouse spleen cells, and performing reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid); s3, preparation of an initial bacteriophage display library: amplifying a heavy chain variable region and a light chain variable region by using a PCR technology, and then assembling to form scFv; constructing scFv phagocytids, electrically transforming the scFv phagocytids into TG1 competent cells, and constructing a bacterial library; s4, constructing a phage single-chain library of the hCD56: infecting the bacterial library by using a helper phage M13K07, and constructing a phage single-chain antibody library; and S5, elutriation and screening of a phage library: specifically enriching a phage single-chain antibody library, screening positive clones from the phage single-chain antibody library, and determining a sequence. According to the invention, the human hCD56 antibody scFv sequence fragment can be screened out, and the research and development period is shortened.

The invention relates to an anti-RSV polypeptide membrane fusion inhibitor as well as a preparation method and application thereof. The invention discloses a compound, a pharmaceutical salt or a derivative thereof, a pharmaceutical composition and a preparation product containing the compound, and application of the compound and the pharmaceutical salt or the derivative in preparation of medicines for preventing and / or treating diseases caused by RSV or other paramyxoviridae viruses. The polypeptide disclosed by the invention shows the anti-RSV activity and safety which are obviously superior to those of positive control polypeptide. Molecular interaction experiments show that the polypeptide acts on the NHR region of the RSV F protein, and the fusion of the RSV virus and a target cell is prevented by forming an inactive six-helix structure with NHR, or by destroying the RSV NHR structure and inhibiting the process of forming a six-helix bundle by NHR and CHR in the F protein in the key step of RSV infection.

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention relates to the technical field of antibodies, in particular to an antibody or an antigen binding fragment specifically binding to avian leukosis virus p27 protein and application of the antibody or the antigen binding fragment. The antibody or the antigen binding fragment contains a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown as SEQ.ID NO.1 or SEQ.ID NO.5, and the amino acid sequence of the light chain variable region is shown as SEQ.ID NO.3 or SEQ.ID NO.7. The antibody or the antigen binding fragment is positive in reaction with the avian leukosis virus, so that the antibody or the antigen binding fragment has good reaction characteristics with the avian leukosis virus.

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention belongs to the technical field of mRNA vaccines, and particularly relates to a self-replicating mRNA vaccine as well as a preparation method and application thereof. The self-replicating mRNA is transcribed from an alphavirus skeleton vector, the alphavirus skeleton vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3 and nsP4 and mutated nsP1, and cysteine at the 492nd position of the mutated nsP1 is mutated into serine. The self-replicating mRNA provided by the invention has higher expression quantity and longer expression time for the target gene. The self-replicating mRNA is used for expressing IMP3 and can be prepared into a vaccine with good prevention and treatment effects on IMP3 positive tumors. Therefore, the invention has a good application prospect in the development of medicines and vaccines.

An antibody-drug conjugate and a preparation method therefor and a use thereof, in particular, an antibody-drug conjugate for treating HER3-positive cancers. The antibody-drug conjugate contains a fully human HER3 antibody, has excellent binding activity to HER3-positive cells, and can efficiently deliver a drug to HER3-positive cells. The antibody-drug conjugate has a good drug-antibody coupling ratio, and has a good targeted killing effect on colon cancer, gastric cancer, breast cancer, and lung cancer (e.g., non-small cell lung cancer, specifically lung adenocarcinoma). Therefore, further provided are a method for preparing the antibody-drug conjugate and a use of the antibody-drug conjugate in treatment of HER3-positive cancers.

The invention relates to a porcine reproductive and respiratory syndrome virus (PRRSV) dimer nucleocapsid (N) protein (PRRSV N-dimer) and application thereof. The PRRSV N-dimer is formed by connecting N protein amino acid sequences in series through (GGGGS) 3linker. According to the invention, a GGGGS 3linker nucleotide sequence is connected in series with a PRRSV NADC30-like strain N protein gene sequence to construct a prokaryotic expression vector, and a recombinant PRRSV N-dimer is expressed in escherichia coli. Through SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and Western-blot detection, the recombinant PRRSV N-dimer obtains soluble expression and can be subjected to a specific reaction with PRRSV positive serum; through detection by a freeze thawing method and an ELISA (Enzyme-Linked Immunosorbent Assay) method, compared with a PRRSV monomer N protein (PRRSV N-monomer), the PRRSV N-dimer protein can be stably preserved, and the immunoreactivity is better. A PRRSV antibody indirect enzyme-linked immunosorbent assay (iELISA) detection method is established on the basis of a PRRSV N-dimer, and can be applied to diagnosis and monitoring of PRRSV infection.

Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3 / CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3 / CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

The invention relates to the related technical field of detection of a porcine respiratory and reproductive disorder virus antibody, and particularly provides a recombinant antigen and an ELISA (enzyme-linked immunosorbent assay) detection kit for detecting the porcine respiratory and reproductive disorder virus antibody based on the recombinant antigen. The invention provides a recombinant antigen. The recombinant antigen is selected from a structure as shown in a formula (I), wherein the AAS1 and the AAS2 independently represent an amino acid sequence as shown in SEQ ID NO.8 or an amino acid sequence as shown in SEQ ID NO.9, and the AAS1 and the AAS2 represent different amino acid sequences; l represents an amino acid sequence # imgabs0 # in the direction from the N terminal to the C terminal, and n is selected from integers from 1 to 5. The recombinant antigen disclosed by the invention can be specifically combined with a porcine respiratory and reproductive disorder virus antibody, so that false positive detection results caused by interfering substances are greatly reduced. (1) AAS1-L-AAS2.

The invention provides a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection kit for mosquito-borne viruses and a detection method of the multiplex fluorescent quantitative PCR detection kit. The detection kit comprises multiple PCR reaction liquid, positive quality control and negative control, the multiplex PCR reaction liquid comprises four specific probes and four pairs of specific primers which are respectively used for detecting the dengue fever virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus; the detection method comprises the following steps: extracting a to-be-detected sample, preparing a PCR mixed solution of a to-be-detected drug, performing PCR amplification and reading a fluorescence signal. Through the mode, the dengue virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus can be specifically recognized, the dengue virus, the Japanese B encephalitis virus, the Zika virus and the west nile virus can be quantitatively detected by combining the standard curve, the detection efficiency is high, the implementation can be stable, the operation is simple, convenient and rapid, and the detection cost is low. The detection speed is high, and the detection accuracy and sensitivity are relatively high.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders.

An anti-BDCA-2 antibody, a preparation method therefor, and a use thereof, relating to the field of antibodies. The preparation method for the anti-BDCA-2 antibody comprises: carrying out ELISA detection and screening on a hybridoma cell culture supernatant and an antigen protein to obtain a positive clone, and subcloning the positive clone to obtain the anti-BDCA-2 antibody. The anti-BDCA-2 antibody comprises a heavy chain and a light chain, wherein a variable region of the heavy chain and a variable region of the light chain are selected from amino acid sequences as shown in SEQ ID NOs: 1-22. The anti-BDCA-2 antibody and related drugs can be used for inhibiting the production of IFN-α by pDCs and preventing the over-activation of the pDCs. The anti-BDCA-2 antibody can effectively inhibit the activation of pDC cells and the production of IFN-α, and has great potential in resisting virus infection and preventing certain autoimmune diseases.

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to HER2.

The invention discloses application of tannin compounds in preparation of drugs for resisting porcine reproductive and respiratory disorder viruses. The inventor of the invention performs activity screening on natural tannin compounds, and finds that the tannin compounds as shown in the formula 1 have excellent anti-PRRSV activity, and the EC50 value of the tannin compounds to PRRSV is lower than or obviously lower than that of ribavirin; therefore, the inhibiting effect of the compounds on the PRRSV is greater than or even far greater than that of a positive control drug ribavirin. The compounds have an unexpected effect of resisting PRRSV (porcine reproductive and respiratory syndrome virus).

The present invention relates to the technical field of veterinary biological products, and in particular to a positive serum for a lumpy skin disease virus, and a preparation method therefor and a use thereof. Healthy negative cattle are inoculated with an inactivated vaccine, the number of inoculations is greater than or equal to 2, and the dose of the inactivated vaccine inoculated each time is larger than or equal to 6 mL, so that a positive serum for a lumpy skin disease virus is finally prepared. The positive serum for a lumpy skin disease virus has a neutralizing antibody titer of ≥1:32, and can be fully applicable to each test item involved in the vaccine development process, so that the present invention solves the bottleneck problem of quality control in the development process of inactivated vaccines for lumpy skin diseases, fills the gap in the preparation process of positive serums for a lumpy skin disease virus, and has important significance for long-term development of veterinary biological product industry.

The invention provides a nucleic acid probe, a primer group, a kit, a detection method and application, and relates to the technical field of biology. The nucleotide sequence of the nucleic acid probe is as shown in SEQ ID NO. 1; wherein the 3'end of the nucleic acid probe is modified with MGB, and locked nucleic acid is modified at a base position corresponding to the difference between the swine fever wild strain and the swine fever vaccine strain in the nucleotide sequence. According to the nucleic acid probe, a specific sequence is utilized to precisely target a swine fever wild strain, and locked nucleic acid modification is introduced at a differential site, so that the recognition capability on single-base mismatch is remarkably enhanced, non-specific binding to a vaccine strain is thoroughly blocked, and false positive interference is eliminated; and 3 '-terminal MGB modification is matched to improve the binding stability and sensitivity, so that the efficient and accurate identification of the swine fever wild strain under the immune background is ensured.

The invention provides a preparation method and application of a genetically modified non-human mammal for producing a humanized antibody. The preparation method comprises the following steps: (1) destroying an endogenous heavy chain immune globulin locus of a non-human mammal; and (2) introducing a human IGHV gene, a human IGHD gene, a human IGHJ gene, and an endogenous IgHG gene, an endogenous IgHE gene, an endogenous IgHA gene and an endogenous LCR region of the non-human mammal into the non-human mammal obtained in the step (1). The non-human mammal prepared by the preparation method disclosed by the invention can efficiently generate a humanized complete antibody or a single-chain antibody or a nano antibody after being immunized by an antigen, and has relatively high immune titer, and moreover, the preparation method disclosed by the invention can be used for obtaining a positive animal with relatively high efficiency, so that the non-human mammal can be used for preparing the non-human mammal. Therefore, humanized mice with different antibody diversity can be easily prepared, and the nanometer antibody sequence diversity can be realized by using various strains of mice.

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

Provided are an anti-B7H3 antibody and the use thereof. A variable region of the antibody comprises amino acid sequences as shown in SEQ ID NOs: 25-39. The anti-B7H3 antibodies 26B6, 6F7, 2B8, and 23H1 have a significant binding capability to B7H3, can not only bind to purified or free B7H3 protein, but also can bind to B7H3 protein on a cell surface; and after humanized modification, the affinity between the antibody and B7H3 is further improved, and the antibody has important application prospects in clinical diagnosis and / or treatment of B7H3-positive tumors.

The invention relates to the field of biological medicines, in particular to an anti-CEACAM5 and CEACAM6 dual-targeting antibody and application thereof, the anti-CEACAM5 and CEACAM6 dual-targeting antibody comprises a heavy chain variable region, and the heavy chain variable region of the anti-CD66e antibody comprises the following technical characteristics: 1t; 1gt; comprising CDR-H1 with an amino acid sequence as shown in SEQ ID No. 1; lt; 2gt; comprising CDR-H2 with an amino acid sequence as shown in SEQ ID No.2; lt; 3gt; comprising CDR-H3 with an amino acid sequence as shown in SEQ ID No.3. The anti-CEACAM5 and CEACAM6 dual-targeting antibody provided by the invention has better affinity, the anti-CEACAM5 and CEACAM6 dual-targeting antibody is used as an antigen binding structural domain to construct a chimeric antigen receptor, the chimeric antigen receptor is used for preparing a CAR-T cell, and the CAR-T cell has killing activity on positive tumor cells of CEACAM5 and / or CEACAM6, can be effectively applied to immunotherapy, and has a good application prospect. The important significance is realized on the development of tumor treatment medicines.

The invention discloses a DNA fragment, a recombinant vector, a reagent combination and a kit for detecting hantavirus HTNV subtypes based on an RPA-CRISPR / Cas12a system, and application of the kit to the non-diagnostic purpose of detecting the hantavirus HTNV subtypes. The detection accuracy of the Hantaan virus can reach 100%, a target substance can be accurately detected, and the probability of false positive or false negative is reduced; meanwhile, the specificity is high, only the Hantaan virus can be detected, and Xinjiang hemorrhagic fever virus, Marburg virus and Ebola virus which have genetic relationship with the Hantaan virus cannot be detected; the method has the characteristics of high efficiency, economical efficiency, convenience and environmental protection of detection at the same time.